86
Participants
Start Date
July 31, 2007
Primary Completion Date
April 30, 2013
Study Completion Date
April 30, 2013
NPI-0052 on Days 1, 8, 15 every 28 days
NPI-0052 dose ranging from 0.1 to 0.9 mg/m2 NPI-0052 IV injection over 1 to 120 minutes on Days 1, 8, and 15 of 4-week cycles
NPI-0052 on Days 1, 4, 8, 11 every 21 days
NPI-0052 dose ranging from 0.075 to 0.6 mg/m2 NPI-0052 IV injection over 1 to 120 minutes on Days 1, 4, 8, and 11 of 3-week cycles
Dexamethasone
20 mg oral or IV day before and day after NPI-0052 dosing.
Peter MacCallum Cancen Center, Melbourne
The Alfred Hospital, Melbourne
Border Medical Oncology, Wodonga
Mater Adult Hospital, South Brisbane
The Queen Elizabeth Hospital, Woodville South
Royal Perth Hospital, Perth
Sir Charles Gairdner Hospital and University of Western Australia, Nedlands
Lead Sponsor
Celgene
INDUSTRY